For more than 20 years, Goodwin Biotechnology has
developed into a uniquely qualified CDMO that provides a Single Source
Solution™ for clients by offering cell
line development, exploratory proof-of-concept
projects through Process Development and cGMP
manufacturing of monoclonal antibodies, recombinant proteins, vaccines, and
biologic drug conjugates including antibody drug conjugates (ADCs) for small
startup ventures to large, multi-national companies as well as government agencies
and medical institutions for early and late stage clinical trials. As part of
their integrated services offerings, Goodwin Biotechnology operates an
ISO5 cGMP filling suite that can accommodate liquid filling of a wide range of
configurations to meet specific and unique client requirements.
Goodwin Biotechnology has successfully completed
numerous traditional Fill / Finish and Drug Product manufacturing projects, as
well as customized, specialized Fill / Finish projects for small volume fills,
light sensitive products, and extremely fragile biological drugs for which
large-scale, automated fill systems are not appropriate.
Most recently, Goodwin Technology was selected to
complete a novel Fill/Finish project, as well as Quality release and stability
testing for a cancer vaccine that is based on the Human Aspartyl (Asparaginyl)
β-Hydroxylase (HAAH) tumor-specific protein. This was geared towards enabling
Phase I clinical trials in patients suffering from various solid tumor cancers.
Panacea Pharmaceuticals, which partnered with Goodwin in this project,
described the Goodwin Biotechnology staff as extremely responsive, flexible,
and solutions oriented. It is easy to see why many companies prefer to work
with Goodwin Biotechnology on their biological projects.
Goodwin Technology has a fill operation that is
fully validated for batch fills up to 2,000 vials per shift and volumes of
0.5mL to 10.0mL per vial. Additional features offered include:
·
Utilization of a programmable pump and
manual fill nozzle (semi-automation) to provide improved yields for small lot
sizes.
·
Vial stoppering immediately after
filling by a second operator before removal from the fill room.
·
Fill checks that are performed at
predetermined levels. For all acceptable fill volumes, this semi-automated
process has consistently met all set standards.
·
Observation and environmental monitoring
of all fill operations by Quality personnel.
·
Monitoring of sealing and fill checks by
Quality personnel.
What’s more, Goodwin Biotechnology has
lyophilization capabilities for small- to mid-scale runs for both GMP and non-GMP
projects, and can accommodate a wide range of vial sizes and configurations. In
addition, Goodwin Biotechnology has successfully provided lyophilization
services for a multinational company to supply GMP material to test a commercially
available product.
Goodwin Biotechnology has an impressive track record
of providing solutions that are customized and tailored to meet specific client
needs. It has in place a comprehensive infrastructure that is required to
deliver quality solutions, such as ready-for-clinical-trials, Final Vialed
Product (FVP). On top of the infrastructure, the team members at Goodwin Biotechnology
are highly skilled and experienced, and as a team, place a great level of
emphasis on quality and being responsive to clients’ needs in an effort to
enhance the value of their drug candidates.
No comments:
Post a Comment